Compare stocks

STTK vs VCYT

Shattuck Labs, Inc. Common Stock and Veracyte, Inc.

Compare the businesses

Shattuck Labs, Inc. Common Stock

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Open STTK dashboard ↗

Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Open VCYT dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗